Multiple Myeloma Committee Meeting Agenda

Chair(s): Paul Richardson, MD
Vice-Chairs: Philip McCarthy, MD

I. Welcome and Introductions

II. Alliance Studies (Completed and Ongoing)
   a. A061202: Phase I/II Pom/Dex +/- Ixazomib (MLN9708) in Relapsed and Refractory MM (RR MM) – Peter Voorhees
   b. A061402: Solitary Osseous Plasmacytoma – Anuj Mahindra
   c. AFT29: Phase II RVd +/- Dara (the Griffin trial) in Newly Diagnosed (ND) MM – Peter Voorhees, Paul Richardson
   d. CALGB 100104 Phase III and derived studies – Phil McCarthy
   e. Auto/Allo in MM (CALGB 100001; Phase I/II) - Phil McCarthy
   f. IFM/DFCI 2009 Study (Phase III BMT CTN 1304; the Determination trial) – Paul Richardson

III. Alliance Studies (Activation Pending)
   a. AFT15: Phase I/II Ibrutinib + Rd in RR MM – Yvonne Efebera

IV. Endorsed Studies
   a. ECOG – E1A11: Phase III RVd vs KRd in ND MM – Edward Faber
   b. ECOG – E3A06: Phase III Smoldering Myeloma (lenalidomide vs placebo) – Anuj Mahindra
   c. SWOG – S1211: Phase III RVd +/- Elo vs KRd +/- Elo; for ND high risk MM – Peter Voorhees
   d. SWOG – S1304: Phase II Carfilzomib in RR MM (completed; results pending) – Peter Voorhees
   e. BMT CTN 1302: Phase II RIC Allo-SCT followed by Ixazomib maintenance in ND MM – Cristina Gasparetto
   f. Amyloid Study – Heather Landau & Hani Hassoun

V. Treatment Concepts and New Initiatives: Updates and New Proposals
   a. AFT35: Phase I/II PVd Dara in RR MM – Hani Hassoun, Paul Richardson
   b. AFT41: Phase II RID +/- Dara in non-SCT eligible ND MM – Betsy O’Donnell, Paul Richardson, Noopur Raje
c. Therapeutic Subcommittee for MM in Older Adults – Tanya Wildes, Sascha Tuchman, Ashley Rosko, Betsy O’Donnell

VI. New Proposals
a. Maintenance after 2nd transplant with Venetoclax – Sarah Holstein and Phil McCarthy
b. Rev +/- ACY241 S/PASCT – Sarah Holstein & Philip McCarthy
c. Optimal duration of lenalidomide maintenance in MRD negative ND MM patients post ASCT – Peter Voorhees
d. Plasma Cell Leukemia- Peter Voorhees
e. CNS Myeloma- Paul G. Richardson
f. Pomalidomide + Ixazomib and dexamethasone in relapsed refractory multiple myeloma (twice a week Ixazomib, in patients who have received 2 or more lines of therapy)- Giada Bianchi, Paul G. Richardson
g. Phase II CyBorD-Dara in monoclonal gammopathy-associated kidney diseases – Hani Hassoun, Sasha Tuchman, Anuj Mahindra, Giada Bianchi

VII. Correlative Science Studies
a. A151210/ A151211: Understanding the molecular basis for myeloid cell transformation in the plasma cell dyscrasias and second malignancies in myeloma – Phil McCarthy
b. Hevylite assay vs standard assays for disease measurement – Hani Hassoun

VIII. Dissemination and Implementation (D&I) Committee Presentation
Sarah Blair MD, FACS and/or Diana Dickson-Witmer MD, FACS